Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2023-182410

Published: 2023

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Matthew J. Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur S. Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika C Banerjee, Anand Rotte, Christopher R Heery, David Avigan, Andrzej J Jakubowiak, Michael R. Bishop

Blood (2023) 142 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2023-189761

Published: 2023

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2023-185309

Published: 2023

Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau

Blood (2023) 142 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2023-187242

Published: 2023

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 743.

https://doi.org/10.1182/blood.V130.Suppl_1.743.743

Published: 2017

Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Blood (2017) 130 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-4.LBA-4

Published: 2017

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Andrew Stefka, MS, David Johnson, Shaun Rosebeck, PhD, Jae-Hyun Park, DVM, PhD, Yusuke Nakamura, MD, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 4415.

https://doi.org/10.1182/blood.V130.Suppl_1.4415.4415

Published: 2017

Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 3110.

https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110

Published: 2017

Journal Articles

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A. Chanan-Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha, Kenneth C. Anderson

Blood (2016) 127 (22): 2693–2700.

https://doi.org/10.1182/blood-2015-12-686378

Published: 2016

Journal Articles

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Paul G. Richardson, Rachid Baz, Michael Wang, Andrzej J. Jakubowiak, Jacob P. Laubach, R. Donald Harvey, Moshe Talpaz, Deborah Berg, Guohui Liu, Jiang Yu, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Sagar Lonial

Blood (2014) 124 (7): 1038–1046.

https://doi.org/10.1182/blood-2014-01-548826

Published: 2014

Includes: Supplemental data

Journal Articles

A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Myo Htut, MD, Jeffrey Zonder, M.D., Joseph W. Fay, MD, Andrzej J Jakubowiak, MD, PhD, Beverly Harrison, Kenneth Lau, BA, Brandi Hilder, Ann Ptaszynski, Selena A Rush, BS, Jonathan L. Kaufman, MD, Steven Michael Burt

Blood (2013) 122 (21): 1938.

https://doi.org/10.1182/blood.V122.21.1938.1938

Published: 2013

Journal Articles

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Ravi Vij, MD, Michael Wang, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Andrzej J. Jakubowiak, MD, PhD, Edward Kavalerchik, MD, Mei Huang, MS, David S. Siegel, MD, PhD

Blood (2013) 122 (21): 1965.

https://doi.org/10.1182/blood.V122.21.1965.1965

Published: 2013

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

NARROW

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only